To understand whether LIF and IL-6 have different effects on the activation of YAP/TAZ-TEAD in pancreatic cancers, we treated serum-starved human pancreatic cancer cells with IL-6 or LIF at 100 ng/mL. This evidence concerns the gene YAP1 and familial pancreatic carcinoma.